AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 123 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 4.38 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $226,068 | -29.5% | 118,983 | +5.4% | 0.01% | -29.4% |
| Q1 2024 | $320,542 | -74.4% | 112,867 | +32.9% | 0.02% | -76.1% |
| Q4 2023 | $1,250,170 | +37.8% | 84,930 | +71.3% | 0.07% | +22.4% |
| Q3 2023 | $907,553 | +119629.9% | 49,566 | +41.1% | 0.06% | +28.9% |
| Q2 2023 | $758 | +26.5% | 35,139 | +72.1% | 0.04% | +21.6% |
| Q1 2023 | $599 | -4.5% | 20,421 | +20.4% | 0.04% | -5.1% |
| Q4 2022 | $627 | – | 16,956 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpha Wave Global, LP | 853,262 | $18,404,861 | 12.06% |
| Stonepine Capital Management, LLC | 1,121,028 | $24,180,574 | 8.72% |
| GREAT POINT PARTNERS LLC | 968,795 | $20,896,908 | 4.09% |
| Ghost Tree Capital, LLC | 550,000 | $11,863,500 | 3.92% |
| Perceptive Advisors | 4,873,919 | $105,130,433 | 3.04% |
| Altium Capital Management LP | 185,000 | $3,990,450 | 3.02% |
| Boxer Capital, LLC | 2,084,000 | $44,952 | 2.08% |
| SECTORAL ASSET MANAGEMENT INC | 387,310 | $8,354,277 | 1.39% |
| AlphaCentric Advisors LLC | 108,000 | $2,329,560 | 1.29% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 680,035 | $14,668,355 | 0.80% |